A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
To learn if the study drug, YL-13027, is safe to give in combination with gemcitabine and nab-paclitaxel to participants with pancreatic cancer.
Metastatic Pancreatic Cancer
DRUG: Gemcitabine|DRUG: Nab-paclitaxel|DRUG: YL-13027
Maximum Tolerated Dose (MTD) and RP2D of YL-13027 in combination with gemcitabine and nab-paclitaxel., Through study completion; an average of 1 year|Overall Response Rate (ORR) of YL-13027 in combination with gemcitabine and nab-paclitaxel, As assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1., Through study completion; an average of 1 year
Primary Objectives

1. To determine the safety and tolerability of YL-13027 in combination with gemcitabine and nab-paclitaxel in participants with refractory metastatic pancreatic cancer.
2. To determine the objective response rate (ORR) of YL-13027 in combination with gemcitabine and nab-paclitaxel in participants with refractory metastatic pancreatic cancer.

Secondary Objectives

1. To evaluate other indicators of the antitumor activity of YL-13027 in combination with gemcitabine and nab-paclitaxel.
2. To evaluate the PK of YL-13027 in combination with gemcitabine and nabpaclitaxel.

Exploratory Objectives

1. To evaluate the PD effects of YL-13027 in combination with gemcitabine and nabpaclitaxel.
2. To evaluate biomarkers of response and resistance to YL-13027 in combination with gemcitabine and nab-paclitaxel.